- Benefit of biosimilar monoclonal antibodies in the therapy of inflammatory bowel diseases2022 | First Faculty of Medicine
- Biosimilar adalimumab in clinical practice2020 | First Faculty of Medicine
- Biosimilar treatment in paediatric gastroenterology - current view2022 | Second Faculty of Medicine
- First clinical experience with biosimilar adalimumab FKB327 in patients with inflammatory bowel disease2020 | First Faculty of Medicine
- Biosimilar infliximab in a clinical laboratory practice2016 | First Faculty of Medicine
- One injection is sufficient2019 | Faculty of Medicine in Pilsen
- How safe are G-CSF biosimilars?2019 | Faculty of Medicine in Pilsen
- Hyrimoz - new biosimilars in treatment of rheumatoid arthritis2019 | Second Faculty of Medicine
- Novels in the therapy of inflammatory bowel disease2017 | First Faculty of Medicine
- Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients - prospective observational study2023 | First Faculty of Medicine
- Age-related macular degeneration2022 | Third Faculty of Medicine
- What are biosimilars and what do they bring to us?2015 | Third Faculty of Medicine
- Biosimilars in treating inflammatory rheumatic diseases2015 | First Faculty of Medicine
- Biosimilar drugs2017 | First Faculty of Medicine, Third Faculty of Medicine